Trials / NCT03146078
Rate of Progression in USH2A-related Retinal Degeneration
Underway, not enrolling Observational Natural history / observational
- Sponsor
- Jaeb Center for Health Research
- Treatment
- Not listed
- Gene
- USH2A
- Conditions
- Usher Syndrome, Type 2A, Retinitis Pigmentosa 39
- Ages
- 8 Years to no upper limit
- Enrollment
- 127 participants
- Started
- 2017-08-11
- Main results expected
- 2023-04-28
- Results posted
- Not yet
- Record last updated
- 2026-10-29
What the study is testing
The overall goal of this project funded by the Foundation Fighting Blindness is to characterize the natural history of disease progression in patients with USH2A related retinal degeneration associated with congenital hearing loss (Usher syndrome type 2a) or non-syndromic retinitis pigmentosa (RP39).
RUSH2A Extension Study: The purpose of this addendum is to extend RUSH2A to 7- and 9-year visits, with the goal to use longer term data to further develop and support early candidate endpoints as possible clinical trial outcomes.
Where it runs
Canada (1)
- Hospital for Sick Children, Toronto
France (1)
- Centre hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris
Germany (1)
- University of Tubingen, Tübingen
Netherlands (1)
- Radboud University, Nijmegen
United Kingdom (1)
- Moorfields Eye Hospital, London
United States (9)
- University of California, San Francisco, San Francisco, California
- Vitreo-Retinal Associates, Gainesville, Florida
- Wilmer Eye Institute at Johns Hopkins, Baltimore, Maryland
- Massachusetts Eye and Ear, Boston, Massachusetts
- Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan
- OHSU Casey Eye Institute, Portland, Oregon
- Retina Foundation of the Southwest, Dallas, Texas
- Baylor Eye Physicians and Surgeons, Houston, Texas
- Moran Eye Center, University of Utah, Salt Lake City, Utah